- Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patients
"At SUO this year, we will present important new data from across our clinical program in High-Risk BCG-Naïve NMIBC and High-Risk BCG-Unresponsive Ta/T1 disease, including results from BOND-003 Cohort P and CORE-008 Cohort A. These updates further reinforce cretostimogene’s potential as a backbone immunotherapy across the NMIBC spectrum. We are grateful to the SUO for providing a leading global forum where meaningful scientific advances can be shared on behalf of patients and their families,” said Ambaw Bellete, President & Chief Operating Officer at CG Oncology.Details on the late-breaking podium presentations and posters are as follows:
Late-Breaking Podium Presentations
Topline Results From BOND-003 Cohort P- a Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ
Presentation Date & Time: December 5, 2025, from 2:30-2:35 PM Mountain Standard Time
Location: Sheraton Phoenix Downtown, Phoenix, AZ
First Results from CORE-008 Cohort A- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer
Presenter: Trinity J. Bivalacqua, M.D., Ph.D., Urologic Oncologist at University of Pennsylvania, Philadelphia, PA
Presentation Date & Time: December 5, 2025, from 2:35-2:40 PM Mountain Standard Time
Location: Sheraton Phoenix Downtown, Phoenix, AZ
Posters
Durable 24-month outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ
Poster Number: 53
Presentation Date & Time: December 3, 2025, from 5-6 PM Mountain Standard Time
Location: Sheraton Phoenix Downtown, Phoenix, AZ
Core-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed Non-Muscle Invasive Bladder Cancer
Trials in Progress
Presenter: Trinity J. Bivalacqua, M.D., Ph.D., Urologic Oncologist at University of Pennsylvania, Philadelphia, PA
Poster Number: 54
Presentation Date & Time: December 3, 2025, from 5-6 PM Mountain Standard Time
Location: Sheraton Phoenix Downtown, Phoenix, AZ
Design and Implementation of Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
Trials in Progress
Presenter: Sarah P. Psutka, M.D. M.Sc., Urologic Oncologist at University of Washington, Seattle, WA
Poster Number: 137
Presentation Date & Time: December 4, 2025, from 2:30 – 3:30 PM Mountain Standard Time
Location: Sheraton Phoenix Downtown, Phoenix, AZ
Source: CG Oncology. (2025). CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Press Release] https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-results-cretostimogene-grenadenorepvec-0